Cytek Biosciences, Inc. (CTKB)
5.59
+0.16
(+2.95%)
USD |
NASDAQ |
Oct 23, 16:00
5.59
0.00 (0.00%)
After-Hours: 20:00
Cytek Biosciences Enterprise Value : 499.78M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 499.78M |
| October 22, 2026 | 478.98M |
| October 21, 2026 | 488.08M |
| October 20, 2026 | 467.29M |
| October 19, 2026 | 455.59M |
| October 16, 2026 | 455.59M |
| October 15, 2026 | 476.38M |
| October 14, 2026 | 474.43M |
| October 13, 2026 | 468.58M |
| October 12, 2026 | 463.39M |
| October 09, 2026 | 478.98M |
| October 08, 2026 | 469.88M |
| October 07, 2026 | 467.29M |
| October 06, 2026 | 472.48M |
| October 05, 2026 | 564.77M |
| October 02, 2026 | 536.18M |
| October 01, 2026 | 528.38M |
| September 30, 2026 | 547.87M |
| September 29, 2026 | 521.88M |
| September 28, 2026 | 519.28M |
| September 25, 2026 | 507.58M |
| September 24, 2026 | 517.98M |
| September 23, 2026 | 511.48M |
| September 22, 2026 | 515.38M |
| September 21, 2026 | 459.49M |
| Date | Value |
|---|---|
| September 18, 2026 | 462.09M |
| September 17, 2026 | 450.39M |
| September 16, 2026 | 413.99M |
| September 15, 2026 | 408.79M |
| September 14, 2026 | 400.99M |
| September 11, 2026 | 372.40M |
| September 10, 2026 | 362.00M |
| September 09, 2026 | 388.00M |
| September 08, 2026 | 373.70M |
| September 04, 2026 | 384.10M |
| September 03, 2026 | 384.10M |
| September 02, 2026 | 382.80M |
| September 01, 2026 | 373.70M |
| August 31, 2026 | 394.49M |
| August 28, 2026 | 381.50M |
| August 27, 2026 | 373.70M |
| August 26, 2026 | 367.20M |
| August 25, 2026 | 368.50M |
| August 24, 2026 | 350.30M |
| August 21, 2026 | 398.39M |
| August 20, 2026 | 378.90M |
| August 19, 2026 | 384.10M |
| August 18, 2026 | 380.20M |
| August 17, 2026 | 389.30M |
| August 14, 2026 | 382.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agilent Technologies, Inc. | 50.99B |
| Bio-Rad Laboratories, Inc. | 9.642B |
| Bruker Corp. | 10.43B |
| Danaher Corp. | 184.25B |
| Harvard Bioscience, Inc. | 75.17M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.16M |
| Revenue (Quarterly) | 48.14M |
| Total Expenses (Quarterly) | 60.30M |
| EPS Diluted (Quarterly) | -0.0939 |
| Gross Profit Margin (Quarterly) | 58.87% |
| Profit Margin (Quarterly) | -25.26% |
| Earnings Yield | -11.22% |
| Normalized Earnings Yield | -11.07 |